{
    "clinical_study": {
        "@rank": "94207", 
        "arm_group": [
            {
                "arm_group_label": "DAR-901", 
                "arm_group_type": "Experimental", 
                "description": "Intradermal administration at 0, 2 and 4 months\nThree dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL"
            }, 
            {
                "arm_group_label": "BCG", 
                "arm_group_type": "Active Comparator", 
                "description": "Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos"
            }, 
            {
                "arm_group_label": "Sterile saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1, randomized, controlled, double-blind, multiple-dose, dose-ranging study\n      of DAR 901, (an inactivated whole cell mycobacterial vaccine) to be conducted in HIV\n      negative and HIV positive adults previously vaccinated with BCG. The goals of the trial are\n      to determine the safety, tolerability, and immunogenicity of multiple doses of the vaccine\n      at different dose levels, ranging from 0.1 to 1 mg."
        }, 
        "brief_title": "Phase I Trial of DAR-901", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All subjects: age 18-65, prior BCG vaccine (scar)\n\n        56 HIV negative subjects: negative ELISA for HIV (48 subjects with negative IGRA, 8\n        subjects with positive IGRA)\n\n        21 HIV positive subjects: positive ELISA for HIV, on ART (13 subjects with negative IGRA,\n        8 subjects with positive IGRA)\n\n        Exclusion Criteria: pregnancy, positive serology for hepatitis B or C, active tuberculosis\n        immunosuppression, severe medical illness\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "77", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063555", 
            "org_study_id": "DAR-901-MDES"
        }, 
        "intervention": [
            {
                "arm_group_label": "DAR-901", 
                "intervention_name": "DAR-901", 
                "intervention_type": "Biological", 
                "other_name": "Inactivated Mycobacterium obuense"
            }, 
            {
                "arm_group_label": "BCG", 
                "intervention_name": "BCG", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Sterile saline", 
                "intervention_name": "Sterile saline", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Tuberculosis", 
            "BCG", 
            "HIV", 
            "TB Vaccines"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "contact": {
                "email": "brenda.haynes@hitchcock.org", 
                "last_name": "Brenda Haynes, RN", 
                "phone": "603-650-5250"
            }, 
            "facility": {
                "address": {
                    "city": "Lebanon", 
                    "country": "United States", 
                    "state": "New Hampshire", 
                    "zip": "03756"
                }, 
                "name": "Dartmouth-Hitchcock Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG", 
        "overall_contact": {
            "email": "fvr@dartmouth.edu", 
            "last_name": "Charles F. von Reyn, MD", 
            "phone": "603 650 7167"
        }, 
        "overall_contact_backup": {
            "email": "timothy.lahey@dartmouth.edu", 
            "last_name": "Timothy Lahey, MD", 
            "phone": "603 650 8840"
        }, 
        "overall_official": {
            "affiliation": "Geisel School of Medicine at Dartmouth", 
            "last_name": "Charles F. von Reyn, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Dartmouth Committee for the Protection of Human Subjects"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will be followed for both systemic side effects and injection site reactions", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "10 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063555"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Cellular and humoral responses to the vaccine antigen will be tested at baseline and after each of 3 doses of vaccine", 
            "measure": "Immunogenicity", 
            "safety_issue": "No", 
            "time_frame": "10 months"
        }, 
        "source": "Dartmouth-Hitchcock Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Aeras", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Dartmouth-Hitchcock Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}